Hendriks J M, Van Schil P E, Van Oosterom A A, Kuppen P J, Van Marck E, Eyskens E
Department of Surgery, Division of Thoracic and Vascular Surgery, University Hospital Antwerp, Edegem, Belgium.
Eur Surg Res. 1999;31(3):267-71. doi: 10.1159/000008702.
Survival after isolated lung perfusion (ILuP) with melphalan was tested in a model of unilateral pulmonary adenocarcinoma.
On day 0, rats were randomized into four groups: Group 1 (n = 9) received tumor cells intravenously for induction of bilateral lung metastases, whereas groups 2-4 (n = 21) underwent a 10-min occlusion of the right pulmonary artery during tumor cell injection for induction of unilateral left lung metastases. On day 7, groups 1 and 2 received no treatment. Group 3 underwent left ILuP with melphalan (2.0 mg/kg) while group 4 received melphalan intravenously (0.5 mg/kg). The end point of the study was death from metastatic disease.
Median survival of ILuP-treated animals (81 +/- 12 days) was significantly longer compared to group 1 (18 +/- 1 days; p = 0.0001), group 2 (28 +/- 3 days; p = 0.0002) and group 4 (37 +/- 6; p = 0.0004).
ILuP with melphalan prolongs survival in the treatment of experimental metastatic pulmonary carcinoma.
在单侧肺腺癌模型中测试了美法仑隔离肺灌注（ILuP）后的生存率。
在第0天，将大鼠随机分为四组：第1组（n = 9）静脉注射肿瘤细胞以诱导双侧肺转移，而第2 - 4组（n = 21）在注射肿瘤细胞期间对右肺动脉进行10分钟的阻断以诱导单侧左肺转移。在第7天，第1组和第2组不接受治疗。第3组接受美法仑（2.0 mg/kg）的左肺隔离灌注，而第4组静脉注射美法仑（0.5 mg/kg）。研究的终点是死于转移性疾病。
与第1组（18±1天；p = 0.0001）、第2组（28±3天；p = 0.0002）和第4组（37±6天；p = 0.0004）相比，接受肺隔离灌注治疗的动物的中位生存期（81±12天）显著更长。
美法仑肺隔离灌注可延长实验性转移性肺癌治疗的生存期。
